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Gut microbiota in HIV–pneumonia patients
is related to peripheral CD4 counts, lung
microbiota, and in vitro macrophage
dysfunction
Meera K. Shenoy1,2,7, Douglas W. Fadrosh1, Din L. Lin1, William Worodria3, Patrick Byanyima3, Emmanuel Musisi3,
Sylvia Kaswabuli3, Josephine Zawedde3, Ingvar Sanyu3, Emily Chang4,5, Serena Fong4, Kathryn McCauley1,
J. Lucian Davis6, Laurence Huang4,5* and Susan V. Lynch1*
Abstract
Pneumonia is common and frequently fatal in HIV-infected patients, due to rampant, systemic inflammation and failure to
control microbial infection. While airway microbiota composition is related to local inflammatory response, gut microbiota
has been shown to correlate with the degree of peripheral immune activation (IL6 and IP10 expression) in HIV-infected
patients. We thus hypothesized that both airway and gut microbiota are perturbed in HIV-infected pneumonia patients,
that the gut microbiota is related to peripheral CD4+ cell counts, and that its associated products differentially program
immune cell populations necessary for controlling microbial infection in CD4-high and CD4-low patients. To assess these
relationships, paired bronchoalveolar lavage and stool microbiota (bacterial and fungal) from a large cohort of Ugandan,
HIV-infected patients with pneumonia were examined, and in vitro tests of the effect of gut microbiome products on
macrophage effector phenotypes performed. While lower airway microbiota stratified into three compositionally distinct
microbiota as previously described, these were not related to peripheral CD4 cell count. In contrast, variation in gut
microbiota composition significantly related to CD4 cell count, lung microbiota composition, and patient mortality.
Compared with patients with high CD4+ cell counts, those with low counts possessed more compositionally similar
airway and gut microbiota, evidence of microbial translocation, and their associated gut microbiome products reduced
macrophage activation and IL-10 expression and increased IL-1β expression in vitro. These findings suggest that the gut
microbiome is related to CD4 status and plays a key role in modulating macrophage function, critical to microbial control
in HIV-infected patients with pneumonia.
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Summary
Gut microbiota composition of HIV-infected patients
with bacterial pneumonia is associated with peripheral
CD4 counts, airway microbiota composition, and in vitro
macrophage dysfunction.
Introduction
Our previous study of a large cohort of Ugandan
HIV-infected acute pneumonia patients identified three
compositionally distinct lower airway microbiota, each
characteristically dominated by a different dominant
bacterial family (Prevotellaceae, Streptococcaceae, or
Pseudomonadaceae) that co-associated with a distinct
group of bacteria [1]. Each of these three lower airway
microbiota was associated with a distinct airway immune
response, and patients with Prevotellaceae-dominated
airway microbiota trended towards significantly higher
patient mortality [1]. However, despite our large cohort,
we did not identify a relationship between airway micro-
biota and CD4 cell status, leading us to speculate that
systemic immune dysfunction underlying susceptibility
to airway infection in HIV-infected patients is influenced
by the gut microbiome and its associated products.
Emerging evidence in both animal [2, 3] and human
[4, 5] studies has demonstrated a role for the gut micro-
biome in the development of airway immune dysfunc-
tion. More specifically, in neonates, perturbation to the
gut microbiome is associated with a significantly in-
creased risk of asthma development in childhood [4].
Such neonatal gut microbiome dysbiosis co-associates
with metabolic dysfunction, including increased concen-
trations of a specific lipid, 12,13 DiHOME, which has
been shown to reduce the frequency of regulatory T cell
populations ex vivo in a dose-dependent manner [4]. In
mice, manipulation of the gut microbiome either via diet
or bacterial supplementation leads to enrichment of me-
tabolites, including microbial-derived fatty acids that
promote immune tolerance, protect against pathogen in-
fection at the airway mucosal surface, and program
pre-cursor cell populations in the hematopoietic com-
partment [2, 3]. Hence, emerging data implicates the gut
microbiome and its metabolic products as playing a key
role in influencing immune function at remote mucosal
sites, including airway responses to pathogenic infection.
It is well established that HIV infection perturbs the gut
microbiota [6], impairs mucosal barrier function, and in-
creases microbial translocation [7]. Within patient popula-
tions in the USA, HIV-associated gut microbiota
perturbation is consistently characterized by increased
relative abundance of Prevotella and Proteobacteria and
decreased Bacteroides abundance [6, 8, 9]. Vujkovic-Cvijin
and colleagues demonstrated that gut dysbiosis is incon-
sistently and only partially rescued with antiretroviral
treatment, while Dillon and colleagues revealed that gut
microbiota dysbiosis associated with HIV infection is asso-
ciated with chronic gut mucosal inflammation [10, 11].
Collectively, these independent microbiota studies dem-
onstrate that HIV infection results in microbial dysbiosis
within respiratory and gastrointestinal niches and
co-associated immune dysfunction, but it has yet to be de-
termined whether such large-scale perturbations occur in
parallel and are related to HIV co-morbidities or to disease
severity as defined by CD4+ cell counts.
We therefore hypothesized that lower airway micro-
biota dysbiosis observed in HIV-infected pneumonia pa-
tients is accompanied by a parallel gut microbiota
perturbation. We further theorized that gut microbiota
composition of HIV-infected pneumonia patients is re-
lated to peripheral CD4 cell count and that the products
of the gut microbiome influence the behavior of immune
cell populations crucial to control of microbial infection.
To investigate this hypothesis, we collected paired lower
airway and stool samples (n = 306) from a large cohort
of Ugandan, HIV-infected patients (n = 153) with pneu-
monia, to address these hypotheses.
Results
Microbiota niche specificity is largely maintained in HIV-
infected patients
Bronchoalveolar lavage (BAL) and stool samples were ob-
tained from Ugandan, HIV-infected patients admitted to
Mulago Hospital for acute pneumonia (n = 153 patients).
Study subjects possessed a median circulating CD4 count of
131 cells μl−1, and almost all were administered antibiotics
prior to undergoing bronchoscopy (for patient characteris-
tics see Additional file 1: Table S1). Bacterial microbiota pro-
files were generated using V4 16S rRNA amplicon
sequencing for lower airway and stool samples. Combined
BAL and stool sample operational taxonomic unit (OTU)
picking (representatively rarefied to 51,997 reads per sample)
and principal coordinates analysis [PCoA (Bray–Curtis dis-
similarity)] of 16S rRNA bacterial sequences revealed that
despite the severely immunocompromised status of this
population, the bacterial communities in these body habitats
are compositionally distinct (Fig. 1a). BAL and stool com-
parisons based on rarified 16S rRNA data was confirmed
with DESeq2, which includes all sequence data and normal-
izes for differences in sequence depth (Additional file 1: Fig-
ure S1). OTU distribution modeling, as previously described
[12], with validation by random forest analysis was used to
identify those bacterial taxa that differentiated stool and
BAL communities; taxa most enriched within the stool were
traditional gut-associated microbes including Bacteroides,
Faecalibacterium, and Ruminococcaceae, while BAL was
characteristically enriched for airway-associated microbes in-
cluding Streptococcus,Veillonella, andHaemophilus (Fig. 1b).
These data demonstrate that despite severe CD4 suppres-
sion, this HIV-infected pneumonia study population largely
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retains site-specific microbiota in the lower airways and
gastrointestinal tract.
Lower airway microbiota stratify into distinct bacterial
microbiota structures
To investigate lower airway microbiota in greater depth,
BAL 16S rRNA sequences were clustered into OTUs (in-
dependently of gut samples) and representatively rar-
efied to 67,135 reads per sample for a final high-quality
data set of 117 airway samples. Consistent with our pre-
vious observations, the lower airway bacterial microbiota
within this cohort displayed distinct compositional pat-
terns related to the dominant bacterial family detected
[permutational multivariate analysis (PERMANOVA,
weighted UniFrac distance, R2 = 0.658, p < 0.001; un-
weighted UniFRAC R2 = 0.118, p < 0.002], and evidence
of either a reciprocal gradient of Prevotellaceae- to
Streptococcaceae-dominance across the majority of sam-
ples (n = 95), or microbiota dominated by genera belong-
ing to the Gammaproteobacteria (n = 16; Fig. 2a). As
previously described, a large majority of lower airway
microbiota were dominated by Prevotellaceae or Strepto-
coccaceae which consistently exhibited co-colonization
with Veillonellaceae and Paraprevotellaceae (Fig. 2b, c).
The remaining Gammaproteobacteria-dominated samples
were primarily dominated by Pasteurellaceae (n = 11) or
Pseudomonadaceae (n = 3), exhibited greater compos-
itional variability, and clustered distinctly from the major-
ity of Prevotellaceae- and Streptococcaceae-dominated
samples (Fig. 2b, c), corroborating our previously pub-
lished observations in an independent cohort [1, 13].
We had also previously reported that Prevotellaceae-
and Streptococcaceae-dominated lower airway micro-
biota were associated with higher bacterial diversity, ad-
ministration of the first-line pneumonia antibiotic
ceftriaxone, and increased detection of cultivable fungi.
In our current study, Prevotellaceae- and Streptococca-
ceae-dominated samples also exhibited significantly
higher Shannon’s bacterial diversity compared with the
Gammaproteobacteria-dominated samples (Kruskal–
Wallis, p < 0.0001; Fig. 2d). Additionally, the majority of
airway microbiota were Prevotellaceae- or Streptococca-
ceae-dominated, which we attribute to the
near-universal administration of ceftriaxone (91%) in this
cohort (see Additional file 1: Table S2 for stratification
of clinical factors by airway microbiota).
To address whether these airway bacterial microbiota
states differentially co-associated with fungi, we also amp-
lified the ribosomal internal transcribed spacer 2 (ITS2)
region from the same DNA extracted for 16S rRNA profil-
ing from BAL samples. Only 26 samples produced a
high-quality fungal profile (representatively rarefied to
1044 reads per sample). The low number of fungal posi-
tive samples is consistent with the clinical observation that
our cohort is a bacterial, rather than fungal pneumonia
patient population. Fungal communities were typically
dominated by Candida (n = 19/26; Additional file 1:
Figure S2A), and unsurprisingly, the dominant fungal
taxon explained a large portion of mycobiota compos-
itional variance across these samples (Bray–Curtis
PERMANOVA, R2 = 0.673, p < 0.001; Additional file 1:
Figure S2B). CD4 count was also found to be related to
airway fungal composition (Bray–Curtis PERMANOVA,
R2 = 0.220, p < 0.01; Additional file 1: Figure S2C). How-
ever, this association was likely driven by Pneumocystis jir-
ovecii-dominated samples (n = 3), all of which were
detected in the most severely immunosuppressed patients
with very low CD4 counts (cells μl−1 < 34). Of note, while
most of our BAL samples produced robust 16S rRNA
amplicons, Pneumocystis-dominated samples did not pro-
duce a bacterial signal. No association was observed be-
tween lower airway fungal and bacterial composition,
which may be due to the relatively small number of fungal
positive samples and the high frequency of co-trimoxazole
administration for Pneumocystis pneumonia prophylaxis
(83%). Nonetheless, consistent with our previous observa-
tions, fungal detection was more common in patients with
Streptococcaceae- and Prevotellaceae-dominated commu-
nities, though due to the small fungal-positive sample size,
this association was not significant (chi-square test, p >
0.05; Additional file 1: Figure S2D).
Finally, we assessed whether lower airway bacterial
community states were related to systemic immune dys-
function as indicated by CD4 status. Consistent with our
previous study, circulating CD4 count (cells μl−1) was
neither associated with airway microbiota composition
variability nor with community state (PERMANOVA,
R2 = 0.009, p = .21; Kruskal–Wallis, p = 0.85; Fig. 2e).
We next asked whether the three observed lower air-
way microbiota states were related to gut microbiota
composition. As a measure of intra-personal airway–gut
microbiota similarity, we calculated Bray–Curtis paired
(See figure on previous page.)
Fig. 1 HIV-infected pneumonia patient stool and BAL exhibit body habitat specificity. a Principal coordinates analysis (PCoA) using Bray–Curtis
dissimilarity of n = 271 bronchoalveolar lavage (BAL; n = 125) and stool (n = 146) bacterial community profiles (including 120 paired BAL–stool
samples) representatively rarefied to 51,997 reads/sample. b Mean difference in reads/sample is plotted for the top 30 taxa differentiating BAL
and stool bacterial communities, identified using linear mixed effects model and false discovery rate q < 0.05, read difference ≥ 100, and presence
in ≥ 50% of the enriched group. PC, principal coordinate; taxa in green were also within the top 30 random forest predictive taxa differentiating
BAL and stool samples
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distance, which weights higher abundance, rather than
phylogenetically related (UniFrac) or lower abundance
(Canberra) taxa. Mean airway–gut microbiota paired dis-
tances did not significantly differ when patients were
stratified by lower airway community state (Kruskal–
Wallis, p = 0.62; Fig. 2f ). Thus, our data indicates that
variation in HIV–pneumonia associated lower airway
bacterial community is neither related to CD4 count nor
to the degree of similarity with gut microbiota compos-
ition. We therefore next determined whether gut micro-
biota related to disease severity and patient outcomes.
Gut microbiota composition is related to clinical and CD4
status
To investigate patient gut microbial communities in
greater depth, stool bacterial 16S rRNA sequences were
clustered at 97% sequence identity into OTUs (inde-
pendent of airway samples) and rarefied to 120,665 reads
per sample (n = 106). Stool bacterial community com-
position was generally characterized by high relative
abundance of Ruminococcaceae, Bacteroidaceae, Entero-
coccaceae, Enterobacteriaceae, or Prevotellaceae with
Ruminococcaceae (Fig. 3a). PERMANOVA analysis of
stool samples revealed that variation in community com-
position was related to demographic, clinical, and micro-
biological factors, but not to sample processing control
variables (Table 1). Of these related factors, dominant
bacterial family explained the greatest proportion of
compositional variance (Bray–Curtis PERMANOVA, R2
= 0.319, p < 0.001; Fig. 3b) and was related to the percent
dominance of the prevailing bacterial family (Kruskal–
Wallis, p < 0.001), suggesting that dominant bacterial
families within the perturbed gut microbiota of
HIV-infected patients relate to the overall structure of
these bacterial communities.
Stool fungal microbiota composition was also investi-
gated using ITS2 rRNA sequencing. Compared with air-
way samples, a much larger proportion of gut samples
produced a high-quality mycobiota profile (n = 90; rar-
efied to 2565 reads per sample). Stool fungal community
composition was also related to dominant fungal family
(Bray–Curtis PERMANOVA, R2 = 0.442, p < 0.001; Add-
itional file 1: Figure S3A), and, similar to BAL fungal
communities, was most frequently dominated by Can-
dida (72/90 samples with 94% mean dominance; Add-
itional file 1: Table S3). Unsurprisingly, given the almost
universally monolithic presence of Candida in the gut
mycobiota of these patients, stool fungal community
composition was not related to patient factors, bacterial
microbiota, or paired airway fungal community compos-
ition (data not shown). Contrary to the clear anatomical
site specificity exhibited by bacterial microbiota, princi-
pal components analysis of mycobiota profiles indicated
no such no site specificity (Additional file 1: Figure S3B
and C). Since stool fungal communities were highly
homogenous across anatomical niches and patients in
our study and did not relate to clinical or immunological
factors, we focused the remainder of our studies on bac-
terial microbiota.
To better understand patient disease, variation in stool
bacterial composition and microbiological characteristics
were examined in relation to patient treatment and out-
comes. Administration of ceftriaxone was significantly
related to stool microbiota composition though it only
explained a minor proportion of variance (Bray–Curtis
PERMANOVA, R2 = 0.019, p = 0.01; Additional file 1:
Figure S4) and did not significantly lower bacterial diver-
sity (Mann–Whitney; p > 0.05). These data indicate that
antimicrobial administration to HIV-infected patients
with pneumonia may not exert large effects on an
already perturbed gut microbiome. Despite a low rate of
mortality within this cohort (6%), mortality at time of
hospital discharge was related to stool microbiota com-
position (Bray–Curtis PERMANOVA, R2 = 0.018, p =
0.017) and to lower Shannon’s diversity compared with
survivors (Mann–Whitney, p < 0.01; Fig. 3c). While stool
bacterial microbiota was related to patient mortality, the
low number of deceased patients limited the power of
this study to detect taxa that consistently differed be-
tween deceased and survivors. Instead, we examined re-
lationships between the gut microbiota and circulating
CD4 count as a marker of disease severity. As expected,
deceased patients in our cohort had significantly lower
CD4 counts (cells μl−1) compared to survivors (Mann–
Whitney, p < 0.01; Fig. 3d). The cohort’s mean CD4
count was 186, median was 131, and range was 1–1010
(See figure on previous page.)
Fig. 2 Three distinct airway microbiota exist in HIV-infected pneumonia patients and relate to microbiological factors, but not to peripheral CD4
count or gut microbiota composition. a Unsupervised hierarchical clustering (using Bray–Curtis dissimilarity (BC) and Ward 2 clustering) of BAL
microbiota and abundance heat map of the top 20 bacterial families present in at least one sample at ≥ 3% relative abundance (ordered from
highest to lowest abundance) indicate distinct but repeating patterns of microbial co-colonization in the lower airways of HIV-infected
pneumonia patients. b Principal coordinates analysis (PCoA) of weighted UniFrac distance for n = 117 BAL samples confirms that significantly
distinct airway microbiota co-associate with dominant bacterial family and explain a large proportion of taxonomic variation in lower airway
bacterial communities (PERMANOVA, R2 = 0.658, p < 0.001). c Mean community composition at the family level for each of the distinct microbiota
community states. Bacterial community states differ in d Shannon’s diversity (KW, p < 0.0001; Mann–Whitney U test p values plotted), but do not
relate to e peripheral CD4 count (cells μl−1; KW p = 0.85) or to f similarity to paired stool sample (paired distance measured using Bray–Curtis; KW,
p = 0.62). PC, principal coordinate; PERMANOVA, permutational multivariate ANOVA; KW, Kruskal–Wallis rank sum test
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Fig. 3 Stool microbiota composition is related to clinical and immunological factors and to CD4 status of HIV-infected pneumonia patients. a
Unsupervised hierarchical clustering (using Bray–Curtis dissimilarity (BC) and Ward 2 clustering) and abundance heat map of the top 20 bacterial
families present in at least one sample at ≥ 3% relative abundance (ordered from highest to lowest abundance) indicate patterns of microbial co-
colonization in stool. b Principal coordinates analysis (PCoA) of BC dissimilarity for n = 106 stool samples illustrates that dominant bacterial family
explains a high degree of variation in bacterial microbiota composition [PERMANOVA, R2 = 0.319, p < 0.001; other = Streptococcaceae (covered by
Enterococcaceae on left) and Porphyromonadaceae]. Mortality at hospital discharge is significantly associated with c stool Shannon’s diversity
(Mann–Whitney U test, p < 0.01) and d CD4 count (cells μl−1; Mann–Whitney U test; p < 0.01). e CD4 count (cells μl−1) is significantly related to
stool dominant bacterial family (Mann–Whitney U test; KW, p = 0.02; only families with > 2 samples are included in this analysis). f CD4 count
(quartile 1 versus 4) is significantly related to stool Faith’s phylogenetic diversity. Similarity between lower airway and stool samples (Bray–Curtis
paired distance) is significantly related to g mortality at hospital discharge (MW, p = 0.01) and h to stool Faith’s phylogenetic diversity (MW, p < 0.03)
when grouped by quartiles and quartile 1 versus 4 are compared. PC, principal coordinate; PERMANOVA, permutational multivariate ANOVA; MW,
Mann–Whitney U test
Table 1 Clinical and microbiological features are significantly associated with variation in stool microbial composition in HIV-
infected patients with bacterial pneumonia
Category Factor PERMANOVAa
R2 p value
Clinical
CD4 count (grouped quartile 1 versus 4) 0.052 0.002
Ceftriaxone at time of sampling 0.019 0.014
Mortality at hospital discharge 0.018 0.017
CD4 count (cells/μl) 0.017 0.025
Pulmonary tuberculosis 0.009 0.499
Ceftriaxone within 3 months prior to hospitalization 0.008 0.634
Microbiological
Dominant family 0.319 0.001
Shannon diversity 0.145 0.001
Paired BAL dominant family 0.122 0.033
Total observed speciesb 0.111 0.001
Faith’s phylogenetic diversity 0.104 0.001
Percent dominance 0.072 0.001
Bray–Curtis distance to paired BAL sample (grouped quartile 1 versus 4)c 0.054 0.002
Bray–Curtis distance to paired BAL sample (continuous) 0.026 0.007
Faith’s phylogenetic diversity of paired BAL sampled 0.021 0.028
Fungal percent dominance 0.022 0.1
Fungal dominant genus 0.095 0.284
Processing
Sequenced on NextSeq run 1 0.012 0.132
Sequenced on NextSeq run 2 0.012 0.132
ITS2 fungal amplicon sequenced 0.013 0.162
16S amplification plate 0.022 0.221
16S primer plate 0.022 0.221
Extraction plate 0.007 0.824
aPermutational multivariate ANOVA results for Bray–Curtis distance shown; representative of weighted and unweighted UniFrac and Canberra distances
bSimilar results for chao1 richness estimate
cSimilar results for weighted and unweighted UniFrac and Canberra distances
dStool composition is not significantly related to BAL richness or Shannon diversity
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cells μl−1 (Additional file 1: Figure S5A). Contrary to the
airway microbiota, CD4 count was significantly associ-
ated with variation in gut microbiota bacterial compos-
ition (Bray–Curtis PERMANOVA, R2 = 0.017, p = 0.025;
Additional file 1: Figure S5B) and with dominant bacter-
ial family, with the lowest CD4 counts associated with
Enterobacteriaceae-dominated gut microbiota (Kruskal–
Wallis, p = 0.02; Fig. 3e). Since the CD4 distribution
within the study population was severely skewed by high
CD4 counts, patients were also sub-grouped by quartile
into CD4 low (cells μl−1 < 34, quartile 1), CD4 intermedi-
ate (34 < cells μl−1 < 293, quartiles 2 and 3), and CD4
high (cells μl−1 > 293, quartile 4) to better understand
the extremes of patient disease within this population
and identify relationships with gut microbiota based on
CD4 count. As with continuous CD4 count, these CD4
subgroups were also significantly associated with stool
bacterial composition (Bray–Curtis PERMANOVA, R2 =
0.052, p = 0.002; Additional file 1: Figure S5C) and the
increase in R2 (3.5%) gained by grouping CD4 count il-
lustrates that consistent compositional patterns are asso-
ciated with low versus high CD4 counts. Patients with
high CD4 counts possessed significantly higher gut
microbiota diversity than those with low CD4 counts
(Mann–Whitney, p < 0.005; Fig. 3f ), confirming that
stool bacterial microbiota diversity and composition are
related to peripheral CD4 count and disease severity.
Gut microbiota composition relates to airway bacterial
community composition
Since stool bacterial microbiota has been shown to regu-
late mucosal immunity at the airway surface [2, 3] and
was related to patient outcomes and to CD4 status in this
study, we next asked whether it related to airway micro-
biota composition. To investigate this, the inter-personal
gut–airway Bray–Curtis similarity indices previously cal-
culated were again used for n = 120 patients who provided
paired airway and stool samples for analyses. The distribu-
tion of these paired distances (P-D) was skewed towards
lower distances (indicative of greater compositional simi-
larity across paired gut and airway microbiota), with mean
distance 0.981, median 0.994, and range 0.810–0.999
(Additional file 1: Figure S6A). Variation in stool micro-
biota composition was significantly related to P-D
(Bray–Curtis PERMANOVA, R2 = 0.026, p = 0.007;
Additional file 1: Figure S6B), indicating that in-
creased airway–gut microbiota compositional similar-
ity (a proxy for shared bacterial taxonomy across gut
and airway body habitats) is related to gut microbiota
composition. P-D was also related to mortality at hospital
discharge; deceased patients exhibited lower P-D values,
i.e., greater microbiota compositional similarity across gut
and airway habitats (Mann–Whitney, p = 0.01; Fig. 3g),
though with the low number of deceased at hospital
discharge within this cohort, this finding is difficult to in-
terpret. To better understand the relationship between
paired distance and stool composition, patients were
stratified based on paired distance quartiles into low
[paired distance (P-D) < 0.9816, quartile 1], intermediate
(0.9815 < P-D < 0.9972, quartiles 2 and 3), and high
(P-D > 0.9971, quartile 4) strata. P-D sub-groups were
related to stool bacterial composition (PERMANVOA;
Bray–Curtis; R2 = 0.054, p = 0.002; Additional file 1:
Figure S5C), and patients with low P-D also possessed
significantly lower gut microbiota diversity than those
with high P-D (Mann–Whitney, p = 0.03, Fig. 3h).
Interestingly, stool and BAL dominant families alone
were not sufficient to explain these relationships be-
tween gut and airway microbiota (Additional file 1:
Figure S7A and B), indicating that lower abundance
microbes within these communities are driving com-
munity similarities. These data indicate that the com-
position of the gut microbiome of HIV-infected
pneumonia patients is related to airway microbiota
composition, to the degree of shared taxonomy across
these body habitats, and to mortality outcomes in our
patient cohort.
Low CD4 count is associated with increased gut–airway
microbiota similarity and taxon sharing across body sites
Since CD4 status was related to gut microbiota compos-
ition, and CD4 depletion is associated with more severe
disease and epithelial barrier dysfunction, we postulated
that patients with lower CD4 counts would exhibit a
higher degree of compositional similarity between their
airway and gut microbiota, indicative of microbial trans-
location between these two body habitats. To examine
this, patients were stratified based on CD4 cell count
(high versus low) and the proportion of those with low
or high airway–gut microbiota P-D was compared. As
hypothesized, patients with low CD4 counts exhibited
significantly smaller gut–airway paired distances indicat-
ing a greater degree of microbiota compositional similar-
ity between these two sites (low P-D; Fisher’s exact test,
p < 0.001; Fig. 4a). To identify taxa that discriminated
CD4-low and CD4-high patient stool microbiota, distri-
bution modeling was performed and validated using ran-
dom forest analysis (Additional file 1: Figure S8). The
stool of HIV-infected patients with high CD4 counts
were enriched for traditional gastrointestinal genera
such as Prevotella, Faecalibacterium, Bacteroides, and
Ruminococcus (Fig. 4b), none of which were detected in
any paired BAL sample of these patients. In contrast,
those patients with low CD4 counts exhibited enrich-
ment of specific Veillonella, Lactobacillales, Streptococ-
cus, and Megasphaera taxa, the latter two of which were
also detected in paired BAL of these patients, implicat-
ing translocation and systemic infection by Streptococcus
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and Megasphaera in the most severely ill HIV-infected
patients (Fig. 4b).
Using stool samples from an independent cohort of
Ugandan, HIV-infected and uninfected patients without
pneumonia, previously examined by Monaco et al [14],
we validated these taxonomic enrichments. Consistent
with our observations, HIV-infected patients with the
highest CD4 counts within the Monaco study were
enriched for members of Prevotella, Ruminococcaceae,
and Bacteroides, whereas those with the lowest CD4
counts were enriched for members of Streptococcus,
Lactobacillus, and Veillonella (Additional file 1: Table
S4). When only untreated HIV-infected patients were
compared to HIV-uninfected patients, Veillonella was
again enriched in the HIV-infected population (Add-
itional file 1: Table S5). Thus, specific gut microbiota
taxonomic perturbations associated with CD4 status are
consistent irrespective of pneumonia or antiretroviral
treatment status in HIV-infected patient populations.
Gut microbial products differentially modulate
macrophage phenotype based on patient CD4 count
Peripheral monocyte-derived macrophages are necessary
for control of lower airway microbial infection and for
resolution of inflammation in pneumonia patients. How-
ever, macrophage dysfunction is a hallmark of advanced
HIV infection and commonly characterized by decreased
circulating monocytes and increased pro-inflammatory
macrophages within the gut [15]. In HIV-infected pa-
tients, pneumonia is not only more common, it is also
frequently fatal due to rampant, systemic inflammation
and failure to control microbial infection. More recently,
it has been demonstrated that the gut microbiome modu-
lates airway immunity and response to respiratory infection
[2–4, 16]. We therefore hypothesized that within the most
severely ill HIV-infected patients, gut microbiota-associated
products promote a pro-inflammatory macrophage effector
phenotype with reduced capacity for tissue repair, contrib-
uting to innate immune dysfunction and failure to control
infection. To investigate this, the THP-1 macrophage cell
line was differentiated for 2 days with phorbol 12-myristate
13-acetate (PMA) prior to 24-h treatment with sterile fecal
water (SFW, see the “Materials and methods” section) from
patients with either the highest or lowest CD4 counts to as-
sess the effect of products of the gut microbiome on
macrophage effector function. Following SFW treatment,
THP-1 cells were assessed via flow cytometry for differenti-
ation (CD14+CD68+), activation (CD80+CD86+),
pro-inflammatory (IL-1β+), and tissue repair (CD206
+IL-10+) markers. While treatment with SFW derived from
CD4 low subjects resulted in significantly fewer activated
macrophages compared with CD4 high subjects (Mann–
Whitney; CD4 p = 0.047, Fig. 5a), a significantly larger pro-
portion of THP-1 cells were pro-inflammatory IL-1β+ mac-
rophages (p < 0.0001, Fig. 5b), and fewer exhibited capacity
for tissue repair (p < 0.01, Fig. 5c; see Additional file 1:
Figure S9 for gating strategy). These observations also held
true when samples were stratified by P-D, which we con-
sider a surrogate for the degree of microbial translocation
in these patients (Additional file 1: Figure S10A-C). Hence,
the associated products of HIV-infected pneumonia patient
stool, the majority of which (70–80% by stool volume) are
microbial-derived, differentially modulate macrophage acti-
vation and differentiation based on patient disease severity
Fig. 4 Patients with low CD4 counts exhibit a greater degree of gut–airway microbiota similarity, loss of gut microbiota commensals, and
evidence of Streptococcus and Veillonella enrichment in both gut and airway microbiota. a Patients with low CD4 counts are significantly more
likely to have low airway–gut microbiota paired distance (quartile 1 versus 4 for each factor, Fisher’s exact test, p < 0.001). b CD4 low (versus high)
patient stool bacterial communities exhibit enrichment of Streptococcus and Megasphaera, which are also enriched in paired airway microbiota
(highlighted in green text), and depletion of microbial genera typically associated with health. Mean differences in reads/sample are plotted for
the top differentiating taxa (genus-level identity provided). Significance was set at a false discovery rate q < 0.05, read difference ≥ 100 reads, and
presence in ≥ 50% of the enriched group. OTU, operational taxonomic unit
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and degree of microbial translocation. These data indicate
that changes in the gut microbiota associated with more se-
vere immune suppression in HIV-infected pneumonia pa-
tients may have meaningful consequences for macrophage
dysfunction and respiratory infection outcomes.
Discussion
The biological factors that determine disease severity
and outcome in HIV-infected patients with pneumonia
are incompletely understood, and prior studies have in-
tuitively focused on the role of the lower airway micro-
biota [1, 17, 18]. Previous investigations of the HIV–
pneumonia lower airway microbiome have described dis-
tinct microbiota composition states dominated by Prevo-
tellaceae, Streptococcaceae, or Pseudomonadaceae (a
member of the Gammaproteobacteria) which differen-
tially relate to airway immune response profile in these
patients, but not to peripheral immune activation status
[1]. This lack of relationship between airway microbiota
and systemic immunity has also been described previ-
ously in cohorts of healthy subjects [1, 19]. Our study
confirms earlier observations noting the existence of
three compositionally distinct lower airway microbiota
in HIV-infected pneumonia patients, each dominated by
a member of the Prevotellaceae, Streptococcaceae, or
Gammaproteobacteria. Also consistent with previous
findings was the observation that Prevotellaceae and
Streptococcaceae dominated communities possessed
similar co-associated microbial taxa that differ primarily
in their relative distribution. Both of these microbiota
states were also significantly more diverse and evidenced
a higher degree of fungal presence compared with the
Gammaproteobacteria-dominated communities. How-
ever, as we have previously found, the airway microbiota
is not related to the degree of disease severity (as defined
by CD4 cell counts), leading us to consider a role for the
gut microbiome in modulating peripheral immune func-
tion and response to bacterial pneumonia in these
patients.
A growing body of evidence implicates the gut micro-
biome in modulating local and remote mucosal immun-
ity, as well as systemic markers of inflammation in
response to microbial infection [3, 6, 16, 20]. Here, we
provide evidence that while both airway and gut micro-
biota are perturbed in parallel in HIV-infected pneumo-
nia patients, it is not the airway, but rather the gut
microbiota that relates to peripheral CD4 cell counts.
Microbial translocation is an established phenomenon
within severely ill HIV-infected individuals who exhibit
CD4+ T cell depletion and mucosal barrier breakdown.
We show that the degree of immune suppression in our
large cohort correlates with increased gut–airway micro-
biota similarity—a surrogate marker of systemic bacterial
infection. HIV-infected pneumonia patients with lower
CD4 counts exhibit a greater degree of shared bacterial
taxonomy in their gut and airway microbiota, and spe-
cific gut-enriched taxa belonging to Streptococcus and
Veillonella are also detected in the airways of these more
severely ill patients, indicating that systemic infection
may be perpetrated by a relatively small number of spe-
cific genera. These findings are pertinent in light of our
re-analysis of the Monaco et al. cohort which indicates
Fig. 5 Sterile fecal water from patients with low CD4 counts reduces macrophage activation, increases IL-1β expression, and decreases the
frequency of tissue repair macrophages. a Compared with CD4-high patients, sterile fecal water from CD4-low patients induces fewer activated
CD80+ CD86+ THP-1-derived macrophages (KW, p < 0.001; all treatments versus media or buffer p < 0.001). b Increased pro-inflammatory IL-1β+
THP-1-derived macrophages are induced by CD4-low compared to CD4-high patient SFW (KW, p < 0.0001; low or intermediate versus media or
buffer p < 0.01, high versus media or buffer p < 0.08). c CD4-low patient sterile fecal water decreased tissue repair associated CD206+ IL-10+ THP-
1-derived macrophages (compared with CD4-high patients; KW, p < 0.001, low versus media or buffer p < 0.05, intermediate or high versus media
or buffer p < 0.06). Low and high subgroups are CD4 count quartiles 1 and 4, respectively. Data representative of two independent experiments;
24 biological replicates with three technical replicates each are plotted. Plotted p values from Mann–Whitney test. KW, Kruskal–Wallis; SFW, sterile
fecal water
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that gut microbiome enrichment of Streptococcus and
Veillonella in HIV-infected patients with low CD4+ cell
counts is more generalizable and occurs irrespective of
pneumonia or HIV treatment, and may be indicative of
traditional airway-colonizing microbes establishing a
niche within the gut or vice versa.
Monocyte-derived macrophages are critical to reso-
lution of lower airway infection and inflammation
[21, 22], particularly in HIV-infected patients with re-
duced capacity to mount an adaptive immune re-
sponse. Progressive HIV infection is known to result
in depletion of circulating monocytes and accumula-
tion of poorly activated, pro-inflammatory macro-
phages within the gut [15, 23]. Independently, it has
been established that the gut microbiome modulates
local and systemic immunity via microbial-derived
products [3, 4, 16, 24] and that gut microbiome dys-
biosis is a hallmark of HIV infection [6, 9, 14]. We
therefore investigated whether sterile, fecal microbial
products from HIV-infected pneumonia patients dif-
ferentially modulate macrophage function in a man-
ner consistent with the immunosuppressive status of
patients in our study. Human stool is primarily com-
posed of microbes (70–80%); thus, sterile fecal water
(SFW) is a reliable source of gut microbial products
and is primarily derived of microbial-derived ligands
and metabolites, with the remaining material made
up of host- or food-derived products. Using the
THP-1 cell line, we demonstrate that SFW from pa-
tients with low CD4 counts is less capable of pro-
moting activated (CD80+CD86+) or tissue repair
(CD206+IL-10+) macrophages compared to CD4-high
patient SFW and instead induces pro-inflammatory
(IL-1β+) macrophages. These results indicate that at
least in vitro, the products of the gut microbiome
from HIV-infected pneumonia patients modulate
macrophage activation and differentiation in a disease
severity-dependent manner. Although our study was
unable to identify a role for the airway microbiota in
this response, it is still unknown whether gut micro-
bial products work in concert with airway microbial
products to induce immune responses and whether
increased sharing of microbes between the lungs and
gut is due to translocation from the gut to the airways,
visa-versa, or an independent source. Nonetheless, it is
plausible that the products of the gut microbiome of
CD4-low patients program pro-inflammatory macrophage
effector phenotypes in vivo, contributing to the failure to
control microbial infection. However, follow-up studies
are necessary to prove whether manipulation of the gut
microbiota independent of the airways can improve pneu-
monia outcomes.
Limitations of this study include its cross-sectional na-
ture and lack of pre-pneumonia paired airway and stool
samples, the latter of which is logistically difficult to ob-
tain in this patient population. It is also important to note
that limited antibiotic and medical history is available for
this patient population. Similar to standard practice in the
USA, HIV-infected individuals hospitalized with suspected
pneumonia in Uganda are invariably treated with empiric
antibiotics while the diagnostic evaluation is in progress
and a recommended first-line antibiotic for hospitalized,
non-ICU patients is ceftriaxone. The vast majority (> 93%)
of patients in this study received ceftriaxone during this
study; however, we were unable to obtain accurate infor-
mation on prior antibiotic use due to lack of medical re-
cords in this population. Despite these limitations, this
study is the first to reveal a systemic microbiota perturb-
ation in HIV-infected pneumonia patients and a relation-
ship between gut microbiota composition and CD4 status.
Moreover, it provides the first evidence that the products
of the gut microbiome of HIV-infected patients with low
CD4 counts alter monocyte effector phenotypes, reducing
their capacity for repair and promoting a program of
pro-inflammatory activity. These investigations add to the
growing body of work implicating the gut microbiome in
airway disease and infection outcomes and suggest that
novel therapeutic strategies that focus on both body habi-
tats may lead to improved outcomes in HIV patients with
acute respiratory infection.
Materials and methods
Study design
We enrolled subjects infected with HIV admitted to
Mulago Hospital in Kampala, Uganda, for acute pneumonia
from June 2012 to November 2015 as part of the Lung
MicroCHIP (Lung Microbiome in Cohorts of HIV-Infected
Persons) study. Patients underwent two sputum acid-fast
bacilli (AFB) smear examinations to diagnose pulmonary
TB. Patients who were sputum AFB smear negative under-
went bronchoscopy with bronchoalveolar lavage (BAL) for
clinical diagnosis, as previously described [1], with 10ml set
aside for microbiome analysis. BAL was performed in the
lung segment that was most involved on chest radiograph.
Bronchoscopy was performed a median of 1 day after hos-
pital admission (interquartile range, 1–3 days) with concur-
rent collection of stool. Clinical data were collected and
diagnoses were assigned as previously described [18]. Study
endpoints were hospital discharge and 2-month vital status.
Ethics statement
The Makerere University School of Medicine Research
Ethics Committee, the Mulago Hospital Research and Eth-
ics Committee, the Uganda National Council for Science
and Technology, and the University of California San
Francisco Committee on Human Research approved the
protocol. Subjects provided written informed consent.
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Bacterial and fungal community profiling
DNA extraction
Individual BAL and stool samples were placed into lys-
ing matrix E (INTEGRA Biosciences) tubes pre-ali-
quoted with 500 μl of hexadecyltrimethylammonium
bromide (CTAB; Sigma Aldrich) DNA extraction buffer
and incubated at 65 °C for 15 min. An equal volume of
phenol:chloroform:isoamyl alcohol (25:24:1; Sigma Al-
drich) was added to each tube, and samples were ho-
mogenized in a Fast Prep-24 homogenizer at 5.5 m/s for
30 s. Tubes were centrifuged for 5 min at 16,000×g, and
the aqueous phase was transferred to individual wells of
a deep-well 96-well plate. An additional 500 μl of CTAB
buffer was added to the LME tubes, the previous steps
were repeated, and the aqueous phases were combined.
An equal volume of chloroform was added to each sam-
ple and mixed followed by centrifugation at 3000×g for
10 min to remove excess phenol. The aqueous phase
(600 μl) was transferred to a deep-well 96-well plate,
combined with two volume equivalents of polyethylene
glycol (PEG) and stored overnight at 4 °C to precipitate
DNA. Plates were centrifuged for 60 min at 3000×g to
pellet DNA, and the PEG solution was removed. DNA
pellets were washed twice with 300 μl of 70% ethanol,
air-dried for 30 min, and suspended in 100 μl of sterile
water. DNA samples were quantitated using the Qubit
dsDNA HS Assay Kit and diluted to 10 or 2 ng/μl for
stool or BAL, respectively. No template controls (NTCs,
one per extraction plate) were processed similar to
samples.
16S DNA amplification and sequencing
The V4 region of the 16S rRNA gene was amplified in
triplicate, as previously described [4]. Triplicate reactions
each possessed one no-template control to assess back-
ground contamination. Triplicate reactions were com-
bined and purified using the SequalPrep Normalization
Plate Kit (Invitrogen) according to the manufacturer’s
specifications. Purified amplicons were quantitated using
the Qubit dsDNA HS Assay Kit and pooled at equimolar
concentrations. For NTCs, total volume was pooled be-
cause burden was too low for equimolar concentrations.
The amplicon library was concentrated using the Agen-
court AMPure XP system (Beckman–Coulter) quanti-
tated using the KAPA Library Quantification Kit (KAPA
Biosystems) and diluted to 2 nM. Equimolar PhiX was
added at 40% final volume to the amplicon library and
sequenced on the Illumina NextSeq 500 Platform on a
153 bp × 153 bp sequencing run.
ITS2 DNA amplification and sequencing
The internal transcribed spacer region 2 (ITS2) of the
rRNA gene was amplified in triplicate, as previously de-
scribed [4]. Amplification and sequencing were performed
with the same protocols as above with the following modi-
fications: PhiX (5 pM final) to the amplicon library and se-
quenced on the Illumina MiSeq Platform on a 290 bp ×
290 bp sequencing run.
16S OTU table generation
Raw sequence data was converted from bcl to fastq for-
mat using bcl2fastq v2.16.0.10. Paired sequencing reads
with a minimum overlap of 25 bp were merged using
FLASH v1.2.11. Successfully merged reads were identi-
fied, had index sequences extracted, and were demulti-
plexed in the absence of quality filtering using QIIME
(Quantitative Insights Into Microbial Ecology, v1.9.1).
Reads were then quality filtered using USEARCH’s fastq
filter (v7.0.1001) to remove reads having > 2 expected er-
rors. Following this step, BAL and stool samples were
both processed individually, as well as part of a com-
bined dataset. Quality-filtered reads were dereplicated at
100% identity, clustered at 97% sequence identity into
operational taxonomic units (OTUs) if they had ≥ 2
reads and had chimeras removed, and mapped back to
the resulting OTUs using USEARCH v8.0.1623. The
Greengenes database (May 2013) was used to assign tax-
onomy to OTUs, and QIIME was used to make the
phylogenetic tree. OTUs were filtered by (1) removing
any known common contaminant OTU present in more
than half of the negative extraction controls for this
study and (2) removing any remaining OTU that had a
total read count across all samples less than 1/5000th of
a percent of the total read counts across all samples for
total OTU picking, or removing any OTU with less than
70 reads for BAL samples and less than 250 reads for
stool samples. Finally, sequencing reads were representa-
tively normalized by rarefying 100 times and using sam-
ple centroids as described previously [4]. Total sample
OTU picking was rarefied to 51,997, BAL alone to
67,135, and stool alone to 120,665 reads per sample.
Total reads from each NTC were below the level of rar-
efying, and NTCs for BAL samples possessed a max-
imum of 2 reads/NTC at dereplication. Raw sequences
from 110 Ugandan HIV-infected and uninfected individ-
uals’ stool samples previously examined by Monaco et al.
[14] were processed in accordance with this pipeline.
OTUs containing less than 1/1000th of a percent of total
reads were removed, and remaining reads were rarefied
to 83,041 reads/sample, resulting in 99 samples retained.
Controlling for low biomass samples
Airway samples (e.g., BAL) are known to possess signifi-
cantly lower bacterial biomass than stool samples in
healthy individuals; to control for the potential of higher
extraction, PCR, and sequencing contamination in these
and in stool samples, several steps were taken. (1) Every
extraction batch had a minimum of one negative control
Shenoy et al. Microbiome            (2019) 7:37 Page 13 of 16
(PBS) per plate, placed in the middle of the plate. These
control extractions were taken through the full sequen-
cing pipeline. (2) PCR for each sample was performed in
triplicate alongside a negative control (H20). Any PCR
with a band in the negative control was rerun. (3) Nega-
tive controls were carried forward with maximum vol-
ume possible at each step of the sequencing pipeline. All
negative controls for BAL samples with the exception of
one failed to sequence. The one BAL negative control
that sequenced possessed two reads, neither of which
made it through quality filtering of the data nor
belonged to an OTU present in real samples. (4) As a
final stringency, low burden OTUs were removed from
all samples (see the “Materials and methods” section) as
a denoising step.
ITS2 OTU table generation
ITS2 OTU tables were generated using the same proto-
col as above with the following modifications and notes:
(1) Chimeras were removed, and taxonomy was assigned
using the UNITE database (January 2016, [25]); (2) no
phylogenetic tree was generated; (3) no NTC success-
fully sequenced; (4) any OTU was removed if it pos-
sessed a total read count less than 1/5000th of a percent
of the total read counts across all samples for total, BAL,
or stool OTU picking; and (5) samples were representa-
tively rarefied to 1000, 1044, or 2565 reads/sample for
total, BAL, or stool OTU picking, respectively.
THP-1 sterile fecal water assay and flow cytometry
Stool samples from 12 CD4-low patients and 12
CD4-high patients were used as biological replicates and
also stratified based on Bray–Curtis paired distance into
6 low, 11 intermediate, and 7 high samples. Samples
were chosen based on CD4-low or CD4-high status and
sufficient material. Stool samples were homogenized 1 g
ml−1 (w:v) in pre-warmed phosphate-buffered saline
(PBS) containing 20% heat-inactivated fetal bovine
serum (FBS). Samples were vigorously vortexed, incu-
bated (37 °C water bath, 10 min), and centrifuged
(14,000×g, 10 min). Supernatant was removed to a new
tube and centrifuged again (16,000×g, 1 h). Supernatant
was filter-sterilized through a 0.4-μm filter, followed by a
0.2-μm filter, before sterile fecal water (SFW) was used
in the THP-1 assay described below. SFW buffer (PBS
with 20% FBS) and R10 media [Roswell Park Memorial
Institute media 1640 with 10% heat-inactivated FBS
(antigen activator) and 2mM L-glutamine and 100 U
ml−1 penicillin–streptomycin added; Life Technologies]
were used as the negative controls.
The THP-1 monocyte cell line (passages 2–3) was cul-
tured for 48 h with 10 ng/ml Phorbol 12-Myristate
13-Acetate (PMA, Thermo Fisher Scientific) added to
R10 media to induce macrophage differentiation. Half of
the culture media was changed to new R10 with SFW
(final SFW concentration 8%) for 24 h. Controls in-
cluded R10 and SFW buffer. To assess cytokine produc-
tion, the cultures were mixed with GolgiPlug (Gplug; BD
Biosciences) for 12 h before staining for flow cytometry.
Experiment was replicated twice due to fecal material
scarcity, with three technical replicates per biological
replicate.
For flow cytometry, single-cell suspensions were
stained using a panel of antibodies, including anti-CD14
(63D3, 1:100; BV711, BioLegend), anti-CD68 (Y1/82A,
1:40; PE-Cy7, BioLegend), anti-CD80 (2D10, 1:50; FITC,
BioLegend), anti-CD86 (IT2.2, 1:50; BV650, BioLegend),
anti-CD206 (15-2, 1:50; APC-Cy7, BioLegend),
anti-IL-1β (H1b-98, 1:20; Pacific Blue, BioLegend), and
anti-IL-10 (JES3-9D7, 1:20; PE, Miltenyi Biotec). Valid-
ation for each primary antibody is provided on the man-
ufacturers’ websites. Dead cells were stained positive
with LIVE–DEAD Aqua Dead Cell Stain (Life Technolo-
gies). Permeabilization buffer (BD Biosciences) was used
to permeabilize cells before staining for the intracellular
markers CD68, IL-1β, and IL-10. For flow analysis, live
THP-1 macrophages were gated as CD14+CD68+ cells.
Among macrophage subpopulations, activated cells were
CD80+CD86+, pro-inflammatory cells were IL-β+, and
tissue repair cells were both CD206+ and IL-10+. Stained
cells were assayed via a flow cytometer on a BD LSR II
(BD Biosciences).
Statistical analysis
Diversity and richness indices were calculated using QIIME.
Distance matrices [weighted UniFrac [26] for BAL com-
parison with previous lung studies; Bray–Curtis for stool
and shared taxa] were calculated in QIIME [27] to assess
compositional dissimilarity between samples and visualized
using PCoA plots constructed in Emperor [28]. Bray–Cur-
tis paired distance was determined using whole dataset
OTU picking (see Additional file 1: Supplemental Methods
for code, [29]). Permutational multivariate analysis of vari-
ance (PERMANOVA) was performed using Adonis in the
R environment (vegan package) to determine factors that
explained variation in microbiota composition (see
Additional file 1: Supplemental Methods for code) and was
used to confirm that BAL and stool composition were not
related to processing factors (p ≥ 0.1). Each clinical, micro-
biological, and demographic factor was initially examined
via PERMANOVA in relationship with microbial compos-
ition. PERMANOVA examines each variable independently
of all other variables examined and does not require add-
itional adjustment against other factors being examined
[30]. We then further examined only those factors which
were statistically significant within PERMANOVA. Un-
supervised hierarchical clustering was performed using the
hclust function in the R environment (stats, heatmap3
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packages) with Bray–Curtis distance (vegan package) and
Ward 2 cluster method on bacterial families present in ≥ 1
sample at ≥ 3% abundance.
To determine which OTUs differed in relative abun-
dance between patient CD4, paired distance, or infection
groups, the distribution of each OTU was modeled using
Poisson, negative binomial, or zero-inflated negative bi-
nomial distributions and the best fit distribution was
assigned based on Akaike information criterion (AIC), as
previously described [12]. This modeling approach is ap-
propriate for sequence-count data, and was corrected
for multiple testing using false-discovery rate [q < 0.05,
see Additional file 1: Supplemental Methods for code,
[31]]. Results were presented if ≥ 50% of the enriched
group possessed the OTU and mean OTU difference be-
tween patient groups was ≥100 reads/sample. Random
forest classification was performed in the R environment
with package randomForest using 5000 trees to validate
OTU distribution modeling (see Additional file 1:
Supplemental Methods for code).
When examining the association between clinical or
microbiological factors and patient groups, p values
were calculated on the basis of covariate distribution
by Kruskal–Wallis (numerical, skewed distribution, >
2 groups), Mann–Whitney (numerical, skewed, 2
groups), chi-square (categorical), or Fisher’s exact
(sparse categorical) tests. To test for THP-1 differ-
ences based on patient group, Kruskal–Wallis was
performed in GraphPad Prism 6. Except where indi-
cated, all analyses were conducted in the R statistical
programming environment.
Additional file
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normalization confirms body habitat specificity of stool and BAL bacterial
communities. Figure S2. Lower airway fungal communities are primarily
dominated by Candida. Figure S3. Similar to lower airways, stool of HIV-
infected pneumonia patients is consistently dominated by Candida and
does not show anatomic site distinction from the lower airways. Figure S4.
The antibiotic ceftriaxone significantly explains a minor proportion of
variance in stool bacterial microbiota. Figure S5. Stool bacterial microbiota
is related to circulating CD4 count. Figure S6. Stool bacterial microbiota
composition differs based on similarity to paired BAL sample. Figure S7.
BAL and stool dominant bacterial family do not relate to one another
within patients. Figure S8. Random Forest confirms CD4 and paired
distance associated enrichments. Figure S9. THP-1 flow gating strategy. Fig-
ure S10. Sterile fecal water from patients with low P-D induce increased ac-
tivated and pro-inflammatory macrophages and decreased tissue repair
macrophage differentiation. Table S1. Clinical and demographic features of
the HIV-infected pneumonia patient cohort. Table S2. Clinical features
across airway microbiota. Table S3. HIV-infected pneumonia patient stool
fungal composition is consistently dominated by Candida or Saccharo-
myces. Table S4. Taxa relatively enriched in the gut microbiota of
CD4 low (white) versus CD4 high (gray) HIV-infected patients (based
on first and fourth quartile respectively; Monaco Study). Table S5. Taxa
relatively enriched in the gut microbiota of HIV uninfected (white) versus
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